Payment overview · 2025
General Payments
$14.83
1 reported records · 1 companies
Healthcare provider profile · identity verified
Thomas Edward Munshower, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · KRESGEVILLE, PA · NPI 1669436432
Verified facts
What the public records show
CMS Open Payments records show Thomas Edward Munshower, D.O. received $14.83 in general payments during 2025 across 1 reported records.
PFIZER INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.83 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $14.83 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 206 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
206 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 591 | 155 |
| Lisinopril | Lisinopril | 458 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 392 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 359 | 89 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 359 | 86 |
| Losartan Potassium | Losartan Potassium | 358 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 280 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 280 | 76 |
| Gabapentin | Gabapentin | 217 | 47 |
| Meloxicam | Meloxicam | 215 | 59 |
| Eliquis | Apixaban | 206 | 44 |
| Omeprazole | Omeprazole | 204 | 62 |
| Furosemide | Furosemide | 183 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 175 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 56 |
| Metformin Hcl Er | Metformin Hcl | 162 | 41 |
| Alprazolam | Alprazolam | 160 | 32 |
| Famotidine | Famotidine | 148 | 37 |
| Simvastatin | Simvastatin | 139 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 36 |
| Metformin Hcl | Metformin Hcl | 135 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 133 | 44 |
| Lorazepam | Lorazepam | 126 | 25 |
| Jardiance | Empagliflozin | 124 | 26 |
| Montelukast Sodium | Montelukast Sodium | 123 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 23 |
| Azithromycin | Azithromycin | 120 | 74 |
| Ozempic | Semaglutide | 106 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 30 |
| Tramadol Hcl | Tramadol Hcl | 104 | 16 |
| Potassium Chloride | Potassium Chloride | 103 | 29 |
| Prednisone | Prednisone | 101 | 42 |
| Sertraline Hcl | Sertraline Hcl | 98 | 22 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 96 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 94 | 27 |
| Allopurinol | Allopurinol | 91 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 84 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 25 |
| Bupropion Xl | Bupropion Hcl | 76 | 16 |
| Januvia | Sitagliptin Phosphate | 76 | 18 |
| Clonidine Hcl | Clonidine Hcl | 71 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 15 |
| Mounjaro | Tirzepatide | 67 | 14 |
| Carvedilol | Carvedilol | 66 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | 13 |
| Warfarin Sodium | Warfarin Sodium | 65 | 12 |
| Atenolol | Atenolol | 60 | 18 |
| Trazodone Hcl | Trazodone Hcl | 60 | 17 |
| Diazepam | Diazepam | 57 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 57 | 15 |
| Xarelto | Rivaroxaban | 56 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 21 |
| Pregabalin | Pregabalin | 52 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 15 |
| Buspirone Hcl | Buspirone Hcl | 49 | suppressed |
| Glimepiride | Glimepiride | 47 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | 12 |
| Ezetimibe | Ezetimibe | 45 | 11 |
| Lovastatin | Lovastatin | 44 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 40 | suppressed |
| Torsemide | Torsemide | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | suppressed |
| Cephalexin | Cephalexin | 38 | 27 |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 29 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 13 |
| Rybelsus | Semaglutide | 37 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Amoxicillin | Amoxicillin | 35 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 12 |
| Celecoxib | Celecoxib | 32 | suppressed |
| Clonazepam | Clonazepam | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Hydrocortisone | Hydrocortisone | 31 | 18 |
| Metolazone | Metolazone | 31 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Nystatin | Nystatin | 30 | 13 |
| Telmisartan | Telmisartan | 30 | suppressed |
| Repaglinide | Repaglinide | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 13 |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 11 |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Klor-Con M10 | Potassium Chloride | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lyrica | Pregabalin | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14.83 · 1 records | PFIZER INC. | ELIQUIS, NURTEC ODT | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error